Lonza has invested into its bioconjugation capabilities at its Visp, Switzerland facility.
The expansion will add two more 1,200 L manufacturing suites, as well as manufacturing-related infrastructure to the current facility.
The novel suites will be suitable for the launch and commercial supply of ADCs, and will generate around 200 new jobs in the area.
Lonza currently estimates that the site will become operational in 2028.
According to the company, the new additions to the Visp site will occupy around 2,000m2 — doubling Lonza's current commercial bioconjugate supply capacity.
The CDMO's suites will be able to serve customers looking to advance their antibody-drug conjugates (ADCs) and other bioconjugates through the drug pipeline, and will be able to assist them form early phase clinical development to large-scale commercial supply.
Drug product filling capacity will also be extended at the site.
Christian Morello, Vice President, Head of Bioconjugates, Lonza, commented: “We continue to see strong growth in the bioconjugates space as ADCs and other bioconjugated drugs increasingly progress towards commercialisation."
"This investment in our multi-purpose commercial bioconjugation capacity addresses the growing market demand, enables us to support the growth of our customers and offers a flexible and integrated service for manufacturing bioconjugates.”
